Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

about

Drug Repurposing for the Treatment of Acute Myeloid Leukemia.Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.

P2860

Q47094576-0B24C898-73B5-498B-9A8D-4E4AD9CA834F Q48579822-61393986-5FA9-4C32-9C5F-AC03FAEF6862

P2860

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Item

http://www.wikidata.org/entity/Q48263650

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@en

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@nl

type

Item

label

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@en

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@nl

prefLabel

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@en

Preventing chemotherapy-induce ...... he FLT3 inhibitor quizartinib.

@nl

P1476

Preventing chemotherapy-induce ...... the FLT3 inhibitor quizartinib

@en

P2093

Catherine A Rinaldi

http://www.w3.org/2001/XMLSchema#string

Emma J Dishington

http://www.w3.org/2001/XMLSchema#string

Johanna M Duyvestyn

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation

Dose translation from animal to human studies revisited

Antineoplastic agents and the associated myelosuppressive effects: a review.

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAM8060

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

402

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28794285

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

about

P2860

P2860

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921